Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
270
Trial Sponsor
Clinical Trial Start Date
December 1, 2021
0Primary Completion Date
October 10, 2023
0Study Completion Date
October 10, 2023
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Prevention0
Intervention Type
Biological0
Intervention Name
UFluA 20 µg each antigen/dose0
UFluA 60 µg each antigen/dose0
Placebo0
Interventional Trial Phase
Phase 10
Participating Facility
Official Name
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study Evaluating Safety and Immunogenicity of Influenza A Hemagglutinin Stabilized Stem Nanoparticle Vaccine Candidate in Healthy Adults0
Last Updated
December 13, 2023
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Double0
Masked Party
Investigator0
Participant0
Study summary
The goal of this Phase 1, single- center, randomized, double blind, placebo-controlled dose-escalation study is to evaluate the safety, tolerability and immunogenicity of UFluA vaccine candidate at two dose levels and two schedules in healthy adult (18-45-year-old, inclusive) male and non-pregnant female subjects.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.